Priya, welcome.
What trends do you see shaping the biopharmaceutical sector
this year?
So, there's a lot of exciting things happening.
There's a significant amount of innovation in this industry.
So, you know, there's been a rise of new modalities, as most
people follow the industry know, with ADCs, cell therapies, gene
therapies, mRNA, all of these new technologies are actually giving
rise to new classes of drugs that are actually, you know,
helping solve diseases that perhaps we couldn't address so
well before.
So I think that's going to be really exciting.
It's been a trend, but it's actually, I think, you're going
to see more, more of that innovation in '25.
And I think that's really exciting for any industry that's
trying to help patients.
So that's what I'm most excited to actually see.
What you're also going to see, on the other hand, is an
industry that is going to face a lot of, lots of exclusivities.
And that brings, I think, a renewed focus on cost.
And how does, how do you leverage technology,
how do you leverage all of the investments in AI, to reduce the
cost of innovation so that you can do more.
What should be top of mind for industry leaders right now?
I think this industry lives and dies by its portfolio.
So doing everything they can to actually be able to spend what
they need to on the innovation engine and then become ultra,
uber-efficient in everything else.
I think that's going to be really, really important for the
industry, for industry leaders.
I think the other thing that will be top of mind for industry
leaders is we also live in a world where there's a lot of
changes, macro changes around us.
And, you know, really understanding those changes and
ensuring that they can protect what is important, which is
really like making sure that patients can actually get the
full benefit of new science.
I think that's the other piece.
And how they navigate that will become really, really important.
Priya, thank you so much for your time.